BPOC
BPOC
BPOC
Pharmaceuticals
BPOC
page 2
Expunere la fum de
Polimorfism genetic
tigara si substante
TGF-b1/ deficit de a1AT
toxice volatile
Citokinele si
proteazele Apoptoza, Scaderea
determina necroza sintezei
degradarea MEC matricei
Contoso
Distrugerea parenchimului pulmonar Pharmaceuticals
page 3
1. Ce este BPOC?
Contoso
Pharmaceuticals
page 4
Mecanisme
Expunerea repetata la substante toxice
fiziopatologice in
determina o inflamatie cronica la nivelul
plamanilor. patogeneza BPOC
Astfel, apare un infiltrat inflamator format din
neutrofile, macrofage si limfocite. Celulele
secreta citokine, elastaze si oxidanti,
contribuind la stresul oxidativ care distruge
MEC prin proteoliza. Produsii de degradare ai
elastinei contribuie la cronicizare.
Contoso
Pharmaceuticals
page 5
Factori de risc in aparitia si evolutia
BPOC
Add Add Add Add Add
Picture Picture Picture Picture Picture
raspunsul Varsta
Deficit Expunere la Fumat celulelor
congenital de a-1 poluanti, mezenchimale la
antitripsina combustibili, agresiuni
subst toxice
page 7
Unique First to Market
Lorem ipsum dolor sit Etiam aliquet eu mi.
amet, consectetur Ut fermentum a
adipiscing elit. magna ut eleifend.
Product
Lorem ipsum dolor sit amet,
consectetur adipiscing elit.
Tested Authentic Etiam aliquet eu mi quis.
Integer convallis Suspendisse sit amet
suscipit eu varius.
Morbi a purus dolor.
ipsum varius finibus
justo viverra blandit.
Contoso
Pharmaceuticals
page 8
Investigatii clinice
pentru diagnostic
BPOC
Contoso
Pharmaceuticals
page 9
Section Divider
Lorem ipsum dolor sit amet, Contoso
consectetur adipiscing elit Pharmaceuticals
page 10
Business Model
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Contoso
Pharmaceuticals
page 11
Market Opportunity Option 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
$1B $2B
• Lorem ipsum dolor sit amet, • Ut congue quis tortor eget
consectetur adipiscing elit. sodales. Nulla a erat eget
nunc hendrerit ultrices eu nec
• Etiam aliquet eu mi quis
nulla.
lacinia. Ut fermentum a
magna ut eleifend. Integer • Donec viverra leo aliquet,
convallis suscipit ante eu auctor quam id, convallis orci.
varius.
• Morbi a purus dolor.
Suspendisse sit amet ipsum
finibus justo viverra blandit.
Contoso
Pharmaceuticals
page 12
Market Opportunity Option 2
Integer convallis suscipit ante eu varius. Morbi a purus dolor.
$3B
Opportunity to Build
$2B
Freedom to Invent
$1B
Few Competitors
Lorem ipsum dolor sit Etiam aliquet eu mi quis Integer convallis suscipit
amet, consectetur lacinia. Ut fermentum a ante eu varius. Morbi a
adipiscing elit. magna ut eleifend. purus dolor.
Contoso
Pharmaceuticals
page 13
Competition Option 1
Contoso
Pharmaceuticals
page 14
Competition Option 2
Convenience
Contoso
Pharmaceuticals
Expensive Affordable
Inconvenient Contoso
Pharmaceuticals
page 15
Growth Strategy
How will we scale in the future
• Lorem ipsum dolor sit • Morbi a purus dolor. • Donec viverra leo
amet, consectetur Suspendisse sit amet aliquet, auctor quam id,
adipiscing elit. ipsum finibus justo convallis orci.
viverra blandit.
• Etiam aliquet eu mi quis • Lorem ipsum dolor sit
lacinia. Ut fermentum a • Ut congue quis tortor amet, consectetur
magna ut eleifend. eget sodales. Nulla a erat adipiscing elit.
Integer convallis suscipit eget nunc hendrerit
ante eu varius. ultrices eu nec nulla.
Contoso
Pharmaceuticals
page 16
Traction
Forecasting for success
20YY 0 0 $0 $0
$250,000
$150,000
20YY 50 500 $33,750 $5,063
$100,000
20YY 200 2000 $135,000 $20,250
$50,000
page 17
Timeline
Our two-year action plan
AUG SEP OCT NOV DEC JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR APR MAY
20YY 20YY
Contoso
Pharmaceuticals
page 18
Financials
Year 1 Year 2 Year 3
Detailers 5,000 40,000 160,000
Users 50,000 400,000 1 600,000
Sales 500,000 4 000,000 16 000,000
Average Price per Sale 75 80 90
Revenue @ 15% 5 625,000 48 000,000 216 000,000
• Cost of Revenue 0 0 0
Gross Profit 5 625,000 48 000,000 216 000,000
Expenses
• Sales & Marketing 5 062,500 38 400,000 151 200,000 70%
• Customer Service 1 687,500 9 600,000 21 600,000 10%
• Product
Development 562,500 2 400,000 10 800,000 5%
• Research 281,250 2 400,000 4 320,000 2%
Total Expenses 7 593,750 52 800,000 187 920,000
Contoso
EBIT -1 968,750 -4 800,000 28 080,000 13% Pharmaceuticals
page 19
Team
Lorem ipsum dolor sit amet, Morbi a purus dolor. Suspendisse sit Donec viverra leo aliquet, auctor quam
consectetur adipiscing elit. Etiam amet ipsum finibus justo viverra id, convallis orci. Sed in molestie est.
aliquet eu mi quis lacinia. Ut blandit. Ut congue quis tortor eget Cras ornare turpis at ligula posuere, sit
fermentum a magna ut eleifend. sodales. Nulla a erat eget nunc amet accumsan neque lobortis.
Integer convallis suscipit ante eu hendrerit ultrices eu nec nulla.
varius.
Contoso
Pharmaceuticals
page 20
Team Alternate
Contoso
Pharmaceuticals
page 21
Funding
$32,000
$82,000
page 22
• Lorem ipsum dolor sit amet, consectetur
adipiscing elit. Etiam aliquet eu mi quis
lacinia. Summary
• Ut fermentum a magna ut eleifend. Integer
convallis suscipit ante eu varius. Morbi a Summary tagline or
purus dolor. Suspendisse sit amet ipsum sub-headline
finibus justo viverra blandit.
• Ut congue quis tortor eget sodales. Nulla a
erat eget nunc hendrerit ultrices eu. Contoso
Pharmaceuticals
page 23
Thank You
April Hansson
+1 23 987 6554
[email protected]
Contoso
www.contoso.com Pharmaceuticals
page 24
Customize this Template
Template Editing
Instructions and Feedback
Contoso
Pharmaceuticals
page 25